Wyszukaj i znajdź CMO/CDMO, którego potrzebujesz

RYNKI: EMA (EU), ANVISA (Brazil), ISP (Chile), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), INVIMA (Colombia), SFDA (Saudi Arabia), TGA (Australia)

REGION: APAC, MENA, LATAM, Europa, Ameryka Północna

ZGODNOŚĆ: DIGEMID, ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), ECOVADIS, TGA (Australia GMP), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority), INVIMA, ISP (Chile BPM), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

ROZMIAR PARTII: Large, Medium

UŻYWAĆ: Human, Veterinary

BSL (poziom bezpieczeństwa biologicznego): 1

USŁUGI: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

TERAPEUTYCZNE OBSZARY WIEDZY (ATC): (J) Antiinfectives for systemic use

SUBSTANCJE KONTROLOWANE: Lowest potential for abuse

OEB (pasmo narażenia zawodowego): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

KATEGORIA / PRODUKT: FDF / PRODUKTY LEKOWE

RYNKI: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), ANMAT (Argentina), MFDS (South Korea), TGA (Australia)

USŁUGI: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europa

ZGODNOŚĆ: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), ECOVADIS, TGA (Australia GMP), INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

ROZMIAR PARTII: Large, Small, Medium

UŻYWAĆ: Human, Veterinary

TERAPEUTYCZNE OBSZARY WIEDZY (ATC): (C) Cardiovascular system, (M) Musculoskeletal system, (N) Nervous system, (A) Digestive tract and metabolism

SUBSTANCJE KONTROLOWANE: Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

OEB (pasmo narażenia zawodowego): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

KATEGORIA / PRODUKT: FDF / PRODUKTY LEKOWE

OEB (pasmo narażenia zawodowego): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

RYNKI: EMA (EU)

REGION: Europa

UŻYWAĆ: Human

BSL (poziom bezpieczeństwa biologicznego): 1, 2

USŁUGI: Manufacturing services, Packaging

ROZMIAR PARTII: Small, Medium

ZGODNOŚĆ: EMA (EU GMP)

KATEGORIA / PRODUKT: BIOLOGIA, FDF / PRODUKTY LEKOWE

BSL (poziom bezpieczeństwa biologicznego): 3, 1, 2

RYNKI: EMA (EU), PMDA (Japan), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MHRA (UK), INVIMA (Colombia), MFDS (South Korea), TGA (Australia)

REGION: Europa

ROZMIAR PARTII: Large, Medium

UŻYWAĆ: Human, Veterinary

USŁUGI: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

TERAPEUTYCZNE OBSZARY WIEDZY (ATC): (C) Cardiovascular system, (D) Dermatologicals, (J) Antiinfectives for systemic use, (N) Nervous system, (R) Respiratory system, (A) Digestive tract and metabolism

SUBSTANCJE KONTROLOWANE: Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

ZGODNOŚĆ: PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), ECOVADIS, INVIMA, ISP (Chile BPM), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

OEB (pasmo narażenia zawodowego): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

KATEGORIA / PRODUKT: FDF / PRODUKTY LEKOWE

RYNKI: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia)

USŁUGI: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europa

ZGODNOŚĆ: DIGEMID, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

ROZMIAR PARTII: Large, Small, Medium

UŻYWAĆ: Human, Veterinary

BSL (poziom bezpieczeństwa biologicznego): 1, 2

OEB (pasmo narażenia zawodowego): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

KATEGORIA / PRODUKT: BIOLOGIA, FDF / PRODUKTY LEKOWE

RYNKI: EMA (EU), MHRA (UK), TGA (Australia)

REGION: Europa

UŻYWAĆ: Human, Veterinary

BSL (poziom bezpieczeństwa biologicznego): 1

USŁUGI: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

OEB (pasmo narażenia zawodowego): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

ROZMIAR PARTII: Small, Medium

ZGODNOŚĆ: EMA (EU GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

KATEGORIA / PRODUKT: FDF / PRODUKTY LEKOWE

BSL (poziom bezpieczeństwa biologicznego): 3, 1, 2

RYNKI: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World

USŁUGI: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

ZGODNOŚĆ: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), ECOVADIS, TGA (Australia GMP), EMA (EU GMP), Health Canada (Canada GMP), MFDS/KFDA (Republic of Korea GMP)

ROZMIAR PARTII: Large, Small, Medium

UŻYWAĆ: Human, Veterinary

SUBSTANCJE KONTROLOWANE: Lowest potential for abuse

OEB (pasmo narażenia zawodowego): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

REGION: Ameryka Północna

KATEGORIA / PRODUKT: FDF / PRODUKTY LEKOWE

RYNKI: EMA (EU), FDA (USA), ANVISA (Brazil), ANMAT (Argentina), MFDS (South Korea), TGA (Australia)

USŁUGI: Logistics, Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging

REGION: Europa

ZGODNOŚĆ: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), ECOVADIS, TGA (Australia GMP), INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

ROZMIAR PARTII: Large, Small, Medium

UŻYWAĆ: Human, Veterinary

TERAPEUTYCZNE OBSZARY WIEDZY (ATC): (C) Cardiovascular system, (J) Antiinfectives for systemic use, (M) Musculoskeletal system, (N) Nervous system, (A) Digestive tract and metabolism

SUBSTANCJE KONTROLOWANE: Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

OEB (pasmo narażenia zawodowego): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

KATEGORIA / PRODUKT: FDF / PRODUKTY LEKOWE

OEB (pasmo narażenia zawodowego): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

SUBSTANCJE KONTROLOWANE: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

RYNKI: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World

USŁUGI: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europa

ZGODNOŚĆ: ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), TITCK (Turkish Health Authorities), NMPA (China GMP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)

ROZMIAR PARTII: Large, Small, Medium

UŻYWAĆ: Human

BSL (poziom bezpieczeństwa biologicznego): 1, 2

TERAPEUTYCZNE OBSZARY WIEDZY (ATC): (H) Systemic hormonal preparations excl. sex hormones and insulins, (L) Antineoplastic and immunomodulating agents, (N) Nervous system

KATEGORIA / PRODUKT: FDF / PRODUKTY LEKOWE

RYNKI: EMA (EU)

REGION: Europa

ZGODNOŚĆ: ISO, EMA (EU GMP)

ROZMIAR PARTII: Large, Medium

KATEGORIA / PRODUKT: NUTRACEUTYKI, FDF / PRODUKTY LEKOWE

UŻYWAĆ: Veterinary

USŁUGI: Manufacturing services, Analytical / QC services, Regulatory services, Packaging

SUBSTANCJE KONTROLOWANE: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

ZGODNOŚĆ: ICH, FDA (cGMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), EMA (EU GMP), Health Canada (Canada GMP), MFDS/KFDA (Republic of Korea GMP)

RYNKI: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), Russian Health Authorities, MFDS (South Korea), TGA (Australia)

ROZMIAR PARTII: Large, Medium

UŻYWAĆ: Human

KATEGORIA / PRODUKT: CHEMICZNO-SYNTETYCZNY, USŁUGI, FDF / PRODUKTY LEKOWE, INŻYNIERIA CZĄSTEK

USŁUGI: Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging

TERAPEUTYCZNE OBSZARY WIEDZY (ATC): (C) Cardiovascular system, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (R) Respiratory system, (S) Sensory organs, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

REGION: Ameryka Północna

OEB (pasmo narażenia zawodowego): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

BSL (poziom bezpieczeństwa biologicznego): 3, 1, 2

SUBSTANCJE KONTROLOWANE: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

RYNKI: EMA (EU), PMDA (Japan), FDA (USA), ANVISA (Brazil), Russian Health Authorities, MHRA (UK), MFDS (South Korea)

REGION: Europa

ROZMIAR PARTII: Large, Small, Medium

UŻYWAĆ: Human

USŁUGI: Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging

TERAPEUTYCZNE OBSZARY WIEDZY (ATC): (C) Cardiovascular system, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (N) Nervous system, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

OEB (pasmo narażenia zawodowego): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

KATEGORIA / PRODUKT: USŁUGI, FDF / PRODUKTY LEKOWE